Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Recent insider selling and the digestion of positive Phase 1 clinical data for CLYM116 are the primary factors influencing short-term sentiment, with the stock currently consolidating following a period of high volatility.
Director Thomas Stephen Basil sold 100,000 shares of common stock on September 15, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. While such sales are routine and planned, they can occasionally trigger short-term negative sentiment regarding insider confidence.
SEC Filing (Form 4)Climb Bio announced positive Phase 1 results for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating a prolonged half-life and potential for every-12-week dosing. This event serves as a fundamental catalyst, though its immediate market impact has been partially absorbed by the stock's recent price action.
SEC Filing (Form 8-K)